Theranostic in nuclear medicine: what is it and what experience do we have in Colombia?
DOI:
https://doi.org/10.53903/01212095.133Keywords:
Theranostic vanomedicine, Positron emission tomography computed tomography, Radionuclide imagingAbstract
In the era of personalized and precision medicine, focused on improving health care by making the most of the opportunities offered by current biomedical, technological, social and economic developments, new terms such as theranostic have appeared. This term was born from the fusion of the concepts of therapy and diagnosis and, although it was proposed in recent years, it refers to an approach that has been used for a long time (1). Theranostic consists of a methodology where the diagnostic approach is focused on individualized therapeutic intervention, seeking to provide the best outcomes for the patient. The area of nuclear medicine has been a pioneer in theranostic, since the first treatment based on this concept was performed with radioactive iodine (131I) in patients with thyroid disease. Currently, with advances in molecular imaging and reporter gene imaging (2), more and more theranostic agents are available to provide individualized or “lesionalized” therapies, as they more recently have come to be called (3). In this review, the theranostic approach in nuclear medicine is exposed, emphasizing how it works, what are the most frequent applications and what experience we have in Colombia.
Downloads
References
Hermann K, Larson SM, Weber W. Theranostic concept: More than just a fashion trend-Introduction and Overview. J Nuc Med. 2017;58(supplement 2):1S-2S.
Kang JH, Chung JK. Molecular-Genetic imaging based on reporter gene expression. J Nucl Med. 2008;49:164S-79S. }
Chung JK, Kim MJ, Youn H. Lesionalized therapy beyond personalized therapy in cancer management. J Korean Med Sci. 2014;29(10):1331-2
Gomez JF, Nunes RE, Coutinho A, Zaniboni E, Costa LB, Barbosa FG, et al. The ranostics in nuclear medicine: Emerging and re-emerging integrated imaging and therapies in the era of precision oncology. RadioGraphics. 2020;40:1715-40
Vbric S, Pejcic I, Filipovic S, Kocic B, Vbric M. Current and future anti-HER2 therapy in breast cancer. J Buon. 2013;18(1):4-16.
Marcu L, Bezak E, Allen B. Global comparison of targeted alpha vs targeted beta therapy for cancer; in vitro and in vivo clinical trials. Crit Rev Oncol/Hematol. 2018;123:7-20
Choudhury PS, Gupta M. Differentiated thyroid cancer theranostics: radioiodine and beyond. Brit J Radiology. 2018;91:1091
Silberstein EB. Radioiodine: the classic theranostic agent. Semm Nucl Med. 2012;42(3):164-70.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force. Thyroid. 2016;26(1):1-133
Kotecka-Blicharz A, Hasse-Lazar K, Handkiewicz-Junak D, Gawlik T, Pawlaczek A, Oczko-Wojciechowska M, et al. 131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumours - a single-centre study. Endokrynol Pol. 2018;69(3):246-51
Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumors with radioiodinated analogue of somatostatin. Lancet. 1989;1(8632):242-4
Singh S, Poon R, Wong R, Metser U. 68Ga PET Imaging in patients with neuroendocrine tumors: A systematic review and meta-analysis. Clin Nucl Med. 2018;43(11):802-10
Levine R, Krenning EP. Clinical history of the theranostic radionuclide approach to neuroendocrine tumors and other types of cancer: historical review based on an interview of Eric P. Krenning by Rachel Levine. J Nucl Med. 2017;58(suppl 2):3S-9S
Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendo - crine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800-16
Rindi G. The ENETS guidelines: the new TNM classifica- tion system. Tumori. 2010;96(5):806-9.
Strosberg J, Wolin E, Chasen B, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018;36(25):2578-84.
Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radio - nuclide receptor therapy: a review. J Nucl Med. 2006;47(9):1467-75.
Hofman MS, Lawrentschuk N, Francis R, Tang C, Vela I, et al. Prostate-specific membrane antigen PET/CT in patients with high-risk prostate cancer before curative intent surgery or radiotherapy: a prospective, randomised, multicentric study. Lancet. 2020;395(10231):1208-16.
Perea M, Papa N, Roberts M, Williams M, Udovicih C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positrón emission tomography in advanced prostate cáncer-Update diagnostic utility, sensitivity, specificity, and distribution of prostate specific membrane antigen-avid lesions: A systematic review and Meta-analysis. European Urol. 2020;77:403-17.
Hofman MS, Violet J, Hicks RJ, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration- resistant prostate cancer (LuPSMA trial): a single-centre, single arm, phase 2 study. Lancet Oncol. 2018;19(6):825-33.
Van Kalmthout LWM, van Melick HHE, Lavalaye J, Meijer R, Kooistar A, de Klerk JMH, et al. Prospective validation of Gallium-68 prostate specific membrane antigen positron emission tomography/computerized tomography for primary staging of prostate cancer. J Urol. 2020;203:537-45.
Wu H, Xu T, Wang X, Yu Y-B, Fan Z-Y, Li D-X, et al. Diagnostic performance og 68Gallium labelled prostate-specific membrane antigen positrón emission tomography/ computed tomography and magnetic resonance imaging for staging the prostate cáncer with intermediate or high riesk prior radical prostatectomy: a systematic review and Meta-analysis. World J Mens Health. 2020;38(2):208-19.
Calopedos RJS, Chalasani V, Asher R, Emmett L, Woo HH. Lutetium-177-labelled anti-prostate-specific mem- brane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017;20(3):352-60.
Ahmadzadehfar H, Wegen S, Yordanova A, et al. Overall survival and response pattern of castration-resistant meta- static prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017;44(9):1448-54
Yordanova A, Eppard E, Kurping S, et al. Theranostics in nuclear medicine practice. OncoTargets Ther. 2017;10:4821-8.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
La Revista Colombiana de Radiología es de acceso abierto y todos sus artículos se encuentran libre y completamente disponibles en línea para todo público sin costo alguno.
Los derechos patrimoniales de autor de los textos y de las imágenes del artículo como han sido transferidos pertenecen a la Asociación Colombiana de Radiología (ACR). Por tanto para su reproducción es necesario solicitar permisos y se debe hacer referencia al artículo de la Revista Colombiana de Radiología en las presentaciones o artículos nuevos donde se incluyan.
